Bicycle Therapeutics (BCYC) Competitors $7.07 +0.05 (+0.71%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.98 -0.09 (-1.27%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. ADPT, TVTX, IMCR, MESO, SRPT, APGE, VCEL, BHVN, EWTX, and AUPHShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Adaptive Biotechnologies (ADPT), Travere Therapeutics (TVTX), Immunocore (IMCR), Mesoblast (MESO), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), Vericel (VCEL), Biohaven (BHVN), Edgewise Therapeutics (EWTX), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors Adaptive Biotechnologies Travere Therapeutics Immunocore Mesoblast Sarepta Therapeutics Apogee Therapeutics Vericel Biohaven Edgewise Therapeutics Aurinia Pharmaceuticals Bicycle Therapeutics (NASDAQ:BCYC) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment. Do analysts rate BCYC or ADPT? Bicycle Therapeutics currently has a consensus target price of $22.22, indicating a potential upside of 214.32%. Adaptive Biotechnologies has a consensus target price of $12.38, indicating a potential downside of 1.86%. Given Bicycle Therapeutics' higher probable upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has more risk and volatility, BCYC or ADPT? Bicycle Therapeutics has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Which has higher earnings and valuation, BCYC or ADPT? Adaptive Biotechnologies has higher revenue and earnings than Bicycle Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$35.28M13.89-$169.03M-$3.51-2.01Adaptive Biotechnologies$178.96M10.73-$159.49M-$0.82-15.38 Is BCYC or ADPT more profitable? Adaptive Biotechnologies has a net margin of -59.07% compared to Bicycle Therapeutics' net margin of -1,257.00%. Bicycle Therapeutics' return on equity of -32.43% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-1,257.00% -32.43% -26.80% Adaptive Biotechnologies -59.07%-60.93%-23.03% Does the media refer more to BCYC or ADPT? In the previous week, Adaptive Biotechnologies had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 6 mentions for Bicycle Therapeutics. Adaptive Biotechnologies' average media sentiment score of 1.21 beat Bicycle Therapeutics' score of 0.54 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in BCYC or ADPT? 86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAdaptive Biotechnologies beats Bicycle Therapeutics on 11 of the 16 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$490M$3.15B$5.79B$10.19BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-2.0121.4375.4026.02Price / Sales13.89419.38514.85113.09Price / CashN/A44.4425.8129.91Price / Book0.629.6112.166.25Net Income-$169.03M-$53.29M$3.29B$270.76M7 Day Performance-1.26%0.13%0.74%3.87%1 Month Performance-4.20%5.55%5.00%5.49%1 Year Performance-73.83%10.44%62.55%25.86% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.2355 of 5 stars$7.07+0.7%$22.22+214.3%-73.8%$490M$35.28M-2.01240ADPTAdaptive Biotechnologies3.6527 of 5 stars$12.54-2.4%$12.38-1.3%+173.5%$1.96B$178.96M-15.29790Positive NewsTVTXTravere Therapeutics2.9772 of 5 stars$21.20-2.0%$33.43+57.7%+74.1%$1.93B$233.18M-10.39460News CoverageAnalyst ForecastIMCRImmunocore2.0303 of 5 stars$36.64-1.5%$56.89+55.3%+5.0%$1.87B$310.20M-91.60320Positive NewsMESOMesoblast2.036 of 5 stars$14.55+1.1%$18.00+23.7%+138.3%$1.84B$17.20M0.0080News CoveragePositive NewsGap DownSRPTSarepta Therapeutics4.4315 of 5 stars$17.60-5.9%$43.50+147.2%-86.0%$1.83B$2.48B-20.231,372Trending NewsAnalyst ForecastAnalyst RevisionAPGEApogee Therapeutics2.9054 of 5 stars$38.42+1.5%$97.29+153.2%-28.2%$1.75BN/A-9.3091News CoveragePositive NewsVCELVericel3.0394 of 5 stars$33.22-2.4%$60.40+81.8%-29.8%$1.72B$249.12M276.86300BHVNBiohaven3.2683 of 5 stars$14.50-8.7%$55.71+284.4%-63.4%$1.68BN/A-1.89239Trending NewsGap DownHigh Trading VolumeEWTXEdgewise Therapeutics2.6275 of 5 stars$14.88-4.4%$40.55+172.5%-24.4%$1.64BN/A-9.6060Positive NewsAUPHAurinia Pharmaceuticals2.8962 of 5 stars$12.30-0.8%$12.00-2.4%+81.2%$1.63B$235.13M28.61300News CoveragePositive News Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Travere Therapeutics Competitors Immunocore Competitors Mesoblast Competitors Sarepta Therapeutics Competitors Apogee Therapeutics Competitors Vericel Competitors Biohaven Competitors Edgewise Therapeutics Competitors Aurinia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts